shortage of glp-1 receptor agonists expected until 2025 Oral Small-Molecule GLP-1 Receptor Agonists:
Description
Charpentier, F
Set up in 1987 in San Diego, Amylin was a small biotechnology company already developing another diabetic drug and agreed to take the gamble with Raufman and Eng's peptide
Increasingly, I am hearing from people who feel mentally and emotionally WORSE , even as their waistlines are shrinking - something some of them have wanted for decades
Lancet 2023, 402, 613626
NEJM Evid
[DOI] [PMC free article] [PubMed] [Google Scholar] 134
